论文部分内容阅读
《新编药物学》第十三版(以下简称《新编药物学》)在内容上较第十二版作了较大的更新和补充,不失为广大医药工作者手头较全面的大型工具书。今从临床药学角度,对该书中的几个问题提出商榷。1 《新编药物学》在平喘药分类上,仍将茶碱类列为磷酸二酯酶抑制剂(第280页),易造成读者对茶碱类平喘药药理机制概念上的局限而影响到临床合理用药。茶碱作为支气管扩张药用于临床已50多年,近10年来对其研究较多,取得较大的进展。据报道,通过实验观察,茶碱试管内抑制磷酸二酯酶(PDE)所需浓度,远远超过治疗有效的人血浆浓度。罂粟碱、潘生丁等作为 PDE 抑制剂,比茶碱更有效,
The new edition of Pharmacology, the thirteenth edition (hereinafter referred to as the “New Pharmacology”) in the content than the twelfth edition made a major update and supplement, after all, the majority of pharmaceutical workers on hand more comprehensive large reference books. From a clinical pharmacy point of view, several issues in the book are open to question. 1 “New Pharmacology” in the classification of asthma drugs, the theophylline is still classified as phosphodiesterase inhibitors (p. 280), easily lead to the reader on the theophylline pharmacological mechanism of antiasthmatic concept of the limitations Affect the clinical rational use of drugs. Theophylline has been used clinically for more than 50 years as a bronchodilator, and more studies have been made on theophylline in recent 10 years, making great progress. It has been reported that by experimental observation, the concentration of phosphodiesterase (PDE) required for in vitro inhibition of theophylline far exceeds that of therapeutically effective human plasma. Papaverine, dipyridamole and the like as PDE inhibitors are more effective than theophylline,